Many advanced cancers develop resistance to treatment and become highly aggressive, often leaving patients with limited treatment options. In some cancers, including lung, pancreatic and prostate tumors, a key driver of treatment resistance and metastasis is a protein called integrin αvβ3, which is absent in normal tissues but enriched in aggressive tumors.
